Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP-214 in acute schizophrenia exacerbation
NCT01625000Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- May 2012
- Primary completion
- Aug 2015
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of cariprazine in schizophrenia (5 arms), sponsored by Mitsubishi Tanabe Pharma. Primary endpoint: Positive and Negative Syndrome Scale Total at 6 weeks. Started May 2012; status: completed.
02
Drugs
cariprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01625000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01625000.